<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, April 5, 2018 (HealthDay News) — The human papillomavirus (HPV) mRNA assays are less sensitive than HPV DNA assays for detection of latent HPV infection, according to a study published online March 8 in Obstetrics & Gynecology<\/i>.<\/p>\n
Sarah Cotton, from the McGovern Medical School at UTHealth in Houston, and colleagues conducted a quality improvement study using data from a pathology laboratory to identify female patients aged 30 years or older with more than one HPV-positive result, including one or more HPV mRNA assay result and one or more documented HPV DNA assay result.<\/p>\n
The researchers identified 425 charts for female patients aged 30 years or older with one or more prior high-risk HPV infections by DNA assay. Compared with previous HPV DNA-positive results, there was a 69.3 percent difference in HPV mRNA results. A potential change in follow-up was seen for 71.7 and 60.0 percent of patients with one prior high-risk HPV-positive result and with two or more prior high-risk HPV-positive results, respectively. A total of 231 colposcopy results were assessed; 26.8 percent were abnormal. Of the abnormal colposcopy findings, 25 (40.3 percent) were in patients with a history of at least two prior HPV DNA-positive results and a current negative mRNA HPV assay.<\/p>\n
“Based on these data and the potential change in follow-up care, the HPV mRNA assay should not be used for a primary screening tool for cervical cancer,” the authors write.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n